Filing Flows

Filing Flows › Companies › Outlook Therapeutics › Cash flow

Outlook Therapeutics cash flow, quarter by quarter

Latest: Q3 FY26 · from the cash-flow statements filed with the SEC

Free cash flow−$21.0M in Q3 FY26 · −$56.2M over twelve months

Operating cash flow−$21.0M
Free cash flow−$21.0M

Analysis

In Q3 FY26, Outlook Therapeutics generated −$21.0M of operating cash flow. That is $9.1M less than in Q3 FY25 (−$11.9M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$56.2M; the largest uses were operating cash flow ($56.2M); besides operations, cash came from shares issued ($54.7M), other financing ($5.9M); the cash balance rose by $2.3M.

Operating cash flow was −$21.0M against net income of −$20.3M. The largest differences: payables −$6.5M, accrued liabilities −$5.8M, prepaid and other assets +$1.9M.

Free cash flow

Outlook Therapeutics: free cash flow by quarterOutlook Therapeutics: free cash flow by quarter−$17.0MQ4 FY24−$11.0MQ1 FY25−$16.6MQ2 FY25−$11.9MQ3 FY25−$12.4MQ4 FY25−$14.9MQ1 FY26−$7.8MQ2 FY26−$21.0MQ3 FY26
Operating cash flow less capital spending.
Outlook Therapeutics: operating cash flow against capital spendingOutlook Therapeutics: operating cash flow against capital spendingOperating cash flowCapital spending−$17.0M$0Q4 FY24−$11.0M$0Q1 FY25−$16.6M$0Q2 FY25−$11.9M$0Q3 FY25−$12.4M$0Q4 FY25−$14.9M$0Q1 FY26−$7.8M$0Q2 FY26−$21.0M$0Q3 FY26
Latest (Q3 FY26): Operating cash flow −$21.0M, Capital spending $0.

Capital allocation, year by year

Outlook Therapeutics: where the cash came from (up) and went (down), by fiscal yearOutlook Therapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedFY21: Operating cash flow −$54.3MFY21: Net borrowing $9.9MFY21: Shares issued $46.3M$56.2MFY21FY22: Operating cash flow −$56.7MFY22: Net borrowing −$2.3MFY22: Shares issued $62.3M$62.3MFY22FY23: Operating cash flow −$43.0MFY23: Net borrowing $19.8MFY23: Shares issued $30.0M$49.8MFY23FY24: Operating cash flow −$68.8MFY24: Net borrowing −$4KFY24: Shares issued $60.3M$60.3MFY24FY25: Operating cash flow −$51.8MFY25: Net borrowing −$3.0MFY25: Shares issued $25.4M$25.4MFY25
Over these 5 years operating cash flow totalled −$275M; the largest uses were operating cash flow ($275M) and net borrowing ($5.4M). Cash-flow statements as filed.

Where the cash came from and went

Outlook Therapeutics: sources (+) and uses (−) of cash, Q3 FY26Outlook Therapeutics: sources (+) and uses (−) of cash, Q3 FY26Shares issued$25.2MOperating cash flow−$21.0MCash drawn (+) / kept (−)−$3.5MNot reconciled−$2.1MOther financing$1.4M
Outlook Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 FY26Outlook Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 FY26Operating cash flow−$56.2MShares issued$54.7MOther financing$5.9MCash drawn (+) / kept (−)−$2.3MNot reconciled−$2.1M

From profit to cash

Outlook Therapeutics: net income to operating cash flow, Q3 FY26Outlook Therapeutics: net income to operating cash flow, Q3 FY26Net income−$20.3MDepreciation & amortization$14KStock-based pay$792KReceivables$1.1MInventory−$1.7MPayables−$6.5MAccrued liabilities−$5.8MPrepaid and other assets$1.9MOperating cash flow−$21.0M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 FY26−$21.0M—$25.2M−$3.5M−$21.0M
Q2 FY26−$7.8M—$6.9M$929K−$7.8M
Q1 FY26−$14.9M—$14.9M−$594K−$14.9M
Q4 FY25−$12.4M−$2.3M$7.6M$818K−$12.4M
Q3 FY25−$11.9M−$907K$14.6M−$1.3M−$11.9M
Q2 FY25−$16.6M—$1.4M−$1.9M−$16.6M
Q1 FY25−$11.0M—$1.7M$9.2M−$11.0M
Q4 FY24−$17.0M—−$115K$17.1M−$17.0M

Outlook Therapeutics: income statement and cash flow

Outlook Therapeutics, Q3 FY25: revenue $1.5M. The chart follows the revenue to costs, profit and cash.

Outlook Therapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.